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Introduction
This is our 6th annual literature review on mechanical circulatory support (MCS)
devices.
Our previous reports for 2014, 2015, 2016, 2017, 2018 were published as open
access articles and were well received by the readers (1-5). In this paper, we
summarize the most interesting and important, from our standpoint, publications
from 2019. As we have done for the past two years, a section on extracorporeal
membrane oxygenation (ECMO) is included and primarily addresses new
developments in veno-arterial ECMO (VA ECMO) use.
Readers who wish to supplement this review, to argue with the author’s
statements or to express their opinions are encouraged to do so by sending letters
to the editor mguglin@iu.edu or posting on our Facebook page at
https://www.facebook.com/TheVADJournal.
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Outcomes
The outcomes for patients on left ventricular assist device (LVAD) support remains
much the same when compared to 2018. The 2019 annual report from the
Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)
confirmed an ongoing shift in the use of LVAD for less acute (profile 3) patients (1).
One-year survival on continuous flow devices was 83%, and 5-year survival was
46%. The one-year survival rates for centrifugal-flow and axial-flow devices were
85% and 84%, respectively. At one year, stroke occurred in 20% of patients on
centrifugal-flow support and 13% of patients on axial-flow support (p < 0.001);
gastrointestinal bleeding (GIB) affected 20% and 25% (p < 0.001); and pumprelated infections occurred in 28% and 25% of patients, respectively (p= 0.01).
Neurologic dysfunction (19% of deaths) and multisystem organ dysfunction (15%)
were the most common causes of death (1).

Device Studies
HeartMate II vs. HeartMate 3
The final analysis from the Multicenter Study of MagLev Technology in Patients
Undergoing Mechanical Circulatory Support Therapy with HeartMate® 3 (HM3,
MOMENTUM 3, Abbott), a randomized trial comparing the HM3 and HeartMate II
(HMII), was published last year (2). Patients were randomly assigned to receive
either the centrifugal-flow (HM3) or the axial-flow pump (HMII) irrespective of the
intended goal of use (bridge to transplantation or destination therapy). At two years
post-implantation, 76.9% in the HM3 group, as compared with 64.8% in the HMII
group, remained alive and free of disabling stroke or reoperation to replace or
remove a malfunctioning device, which was the primary endpoint of the trial
(relative risk, 0.84; 95% confidence interval [CI], 0.78-0.91; P < 0.001 for
superiority). Pump replacement at two years, the secondary endpoint, was less
common in the centrifugal-flow pump group than in the axial-flow pump group
(2.3% vs. 11.3%; relative risk, 0.21; 95% CI, 0.11-0.38; P < 0.001). The numbers
of events per patient-year for a stroke of any severity, major bleeding, and
gastrointestinal hemorrhage were lower in the centrifugal-flow pump group than in
the axial-flow pump group. There was no significant difference in overall survival
between the groups (2).
A substudy of the same trial compared strokes in patients supported with these
two pumps and found that the HM3 pump was associated with a marked reduction
in stroke rates compared with the HMII (3). Although there was no short-term
difference in stroke rate (up to 180 days), stroke incidence in the long-term period
(181-730 days after LVAD) was 3.3 times lower for the HM3 group (HM3: 0.04
versus HMII: 0.13 events per patient-year; odds ratio, 0.23; 95% CI, 0.08-0.63; P=
0.01). There was no direct association of blood pressure (BP) or antithrombotic
regimens with observed stroke rates. A stroke significantly lowered 2-year survival:
43 ±12% for hemorrhagic stroke, 57±9% for ischemic stroke, 51 ±11% for
disabling, and 51 ±11% for nondisabling compared with 85 ±2% 2-year survival for
patients without stroke (3).
Importantly, as compared to other continuous-flow pumps, the HM3 is likely related
to lower shear stress due to its fully magnetically levitated rotor. It is well known
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that von Willebrand factor (vWF) and acquired von Willebrand syndrome play a
major role in the origin of GIB complications in patients with continuous-flow
LVADs. In a study published from the Continued Access Protocol of the
MOMENTUM3 trial, the high molecular weight multimers of vWF were better
preserved in the HM3 than in HMII supported patients (4). Also, patients with HM3
devices had a higher level of vWF activity during device support, which may
reduce the formation of arteriovenous malformations and lead to a lower bleeding
complication rate (5).

Fully-Implantable LVAD
There is a consensus in the MCS world that eliminating the driveline and all
associated problems would be a breakthrough leading to a dramatically improved
quality of life for patients with LVADs. A fully implantable LVAD option would
increase the appeal of this intervention to patients, families, and physicians. Last
year, two human patients received fully-implantable LVADs (LeviticusCardio, Ltd.,
Petach Tikva, Israel) in Astana, Kazakhstan (6). The system was integrated with
the Jarvik 2000 (Jarvik Heart, Inc.) and consists of an internal integrated controller
and battery coupled with an internal thoracic coil ring designed for energy
harvesting. The required energy was delivered to the device via a coplanar energy
transfer system comprised of two large rings utilizing a coil-within-the-coil topology.
This system ensures robust resonance energy transfer while allowing for
substantial (>6 hours) unholstered circulatory support powered by an implantable
battery source. The external equipment includes a power transmission belt
coupled with an external controller, battery, and wristwatch monitor. One patient
had early pump thrombosis and a perioperative stroke with a major residual deficit.
The second patient reached full ambulation, including swimming, within the first
week of surgery, was discharged from the hospital, and successfully transplanted
thereafter (6).

Figure 1. A. Chest X-ray depicting implantable components topography, B.
Implantable components C. External components. Reproduced from Pya et al. (6),
with permission
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Candidate Selection
Most programs do not have a rigid upper age limit for LVAD candidates.
Nevertheless, it is important to remember that elderly patients are at a survival
disadvantage. A majority (84.5%) of younger patients (< 55 years old) are
discharged to home, but only 46.8% of adults over 75 years of age were
discharged home following implantation (p < 0.001) (7). Post-implantation survival
was 69.6%, 46.2%, and 31.7% at 1-, 3-, and 5-years in patients older than 75
years of age, respectively, which is starkly different than the respective survival
rates (87.7%, 70.3%, and 53.7%) of patients less than 55 years of age (p < 0.001)
(7).
Also, elderly patients with LVADs had a higher incidence of GIB but lower rates of
device thrombosis (adjusted hazard ratio [HR] for GIB: 2.52; 95% CI, 2.24-2.84)
compared to those younger than 55 years of age (7). On the other hand, the
hazard ratios of pump thrombosis were lower in the oldest cohort (adjusted HR,
0.40; 95% CI, 0.31-0.52), which might justify a lower intensity of anticoagulation in
this population (7).
Pulmonary vascular resistance (PVR), calculated as a transpulmonary gradient
(mean pulmonary artery pressure minus pulmonary capillary wedge pressure)
divided by cardiac output, is routinely calculated during transplant/LVAD
evaluation. According to Uriel et al. (8), the transpulmonary gradient, which is
directly measured, rather than calculated, and therefore is less susceptible to
error, is more valid for prognosis. However, the transpulmonary gradient scores
did not predict survival while on LVAD support. In patients who were successfully
transplanted after being bridged with LVAD, a transpulmonary gradient of >10 mm
Hg, which was the median on pre-LVAD measurement, was associated with
reduced one-year survival rates (80% vs. 91%; p = 0 .016). To the contrary, below
or above the median PVR pre-LVAD did not impact survival rates (8).
The pulmonary function study, which is another routine test during candidate
selection, does not appear useful. There was no association between baseline
pulmonary function tests and survival time post-LVAD or the incidence of
perioperative right ventricular (RV) failure (9).
Another study looked into candidates who were referred for LVAD evaluation and
were rejected by the selection committee at a single center (10). Their yearly
acceptance rate ranged between 57% and 75%. Reasons for rejection included:
patient being too sick (34%); psychosocial concerns (25%); patient declined
(16%); decision was deferred for medical optimization (15%); or patient being too
healthy (10%). Psychosocial concerns included poor social support (71%), a
history of non-compliance (16%), and a history of drug abuse (13%) (10). The oneyear survival of rejected patients was 42% in those who were too sick, 64% in
those with psychosocial concerns, 68% in patients who declined, 86% in those
deferred for medical optimization, and 100% in those too healthy (P < 0.01). A
subset analysis of 40 patients who were rejected because of poor social support
had a 46% one-year mortality (10). These data may be a sign that increasing
flexibility in patient acceptance by the programs may be beneficial for the patients.
Denial of a life-saving device because of circumstances that the patient cannot
control sentences them to a 50% chance of death in the next year. While we all
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want our patients with LVADs to be safe, the rate of life-threatening situations on
LVAD support is certainly less than 50% a year.

Management of Patients on LVAD Support
Multidisciplinary team
Last year, the Montefiore LVAD program implemented a number of changes in
their protocols that were associated with a significant increase in one-year survival
(74.6% to 100% [p= 0.0002]) (11). Further, one-year survival free of serious
adverse events (reoperation to replacement of the device or disabling stroke)
increased from 70.4% to 84.9% (p= 0.059). At the same time, rates for disabling
stroke, measured as event per patient-year, decreased from 0.15 to 0, (p= 0.019).
Rates of GIB decreased from 0.87 to 0.51 (p= 0.11) as did driveline infection rates
(0.24 to 0.10, p= 0.18). The changes included:
- daily, simultaneous cardiology/cardiac surgery/critical care/pharmacy/coordinator
rounds
- pharmacist-directed anticoagulation
- speed optimization echocardiogram before discharge
- comprehensive device thrombosis screening and early intervention
- use of a BP clinic with pulsatility-adjusted goals
- early follow-up after discharge
- individual long-term coordinator/cardiologist assignment
- systematic training and credentialing of ancillary in-hospital providers (11).

Emergencies on LVAD
The Heart Failure Society of America, the Society for Academic Emergency
Medicine, and the International Society for Heart and Lung Transplantation
published an expert consensus document that included a decision matrix to guide
the management of emergencies in LVAD patients (12).

Figure 2. Modified flowchart from Givertz et al. (12).
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For comparison, we are reproducing our own algorithm published in the VAD
Journal (13).

Figure 3. Approach to Unresponsive patient with LVAD (13)

Optimization of Blood Pressure
The discussion regarding optimal BP and BP control in patients with LVADs is
ongoing. According to a study of INTERMACS data, patients with chronically low
mean arterial pressure (MAP, ≤ 75 mm Hg), Doppler (≤ 80 mm Hg), and systolic
BP (< 90 mm Hg) had a 35%-42% higher adjusted HR of death as compared to
patients with a normal or high BP (p ≤ 0.0001) (14). At the same time, patients with
higher than normal BP (MAP > 100 mm Hg, Doppler ≥ 105 mm Hg, and systolic
BP ≥ 120 mm Hg) had a 17%-20% higher adjusted HR of death than those with
normal pressures (p < 0.05). In patients with axial-flow LVADs, elevated systolic
BP but not MAP correlated with an increased incidence of stroke (HR, 1.07; 95%
CI, 1.03−1.11) per 10 mm Hg increase in systolic BP (P= 0.001). Of note, patients
in the low MAP and Doppler groups were also more likely to have increased
incident RV failure (p < 0.001). Authors suggest that overaggressive
pharmaceutical management of BP in patients with LVADs should be avoided
because excessive afterload reduction may be, in fact, harmful. In general, MAP
between 75 and 90 mm Hg seems to be optimal, while deviations in either
direction are associated with less favorable outcomes (14).
When arterial line BP and Doppler opening pressure were measured
simultaneously, Doppler opening pressure had a good correlation with invasive
MAP (r= 0.742, P < 0.0001) and more closely approximated MAP than systolic BP.
Therefore, Doppler opening pressure might be an acceptable, standard noninvasive method of BP measurement (15).
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Optimization of Hemodynamics
The importance of achievement and maintenance of optimal hemodynamics in
patients with LVAD has gained more and more recognition. In last year’s review,
we cited a paper by Imamura et al. that demonstrated a decreased rate of all
adverse events in LVAD patients if hemodynamics were normal or near normal
(16). There are two ways to improve hemodynamics in LVADs: 1) adjust pump
parameters and/or 2) maximize the performance of the native left ventricle (LV) by
using guideline-recommended heart failure (HF) drugs. The following details the
new developments of 2019:

1) Ramp test
The same group of authors (Imamura et al) (17) published a 2019 study
(seemingly with some overlap with the previous paper) where LVAD speed
was optimized using a ramp test, targeting the following goals: central
venous pressure, < 12 mm Hg; pulmonary capillary wedge pressure, < 18
mm Hg; and cardiac index > 2.2 L/min/m2. The total hospital readmission
rate was lower in the optimized group compared with the non-optimized
group (1.15 versus 2.86 events/year, p < 0.001). This result was
predominantly because of a reduction in the HF readmission rate in the
optimized group (0.08 versus 0.71 events/year, p= 0.016). Survival was
similar. In 39% of patients, hemodynamics could not be optimized. This
was most frequently due to a lower pulmonary artery pulsatility index,
inability to decrease central venous pressure to normal levels, or because
of coexisting atrial fibrillation (17).
Curiously, a novel method of estimation of central venous pressure in
patients with LVADs and biventricular pacemakers was suggested by
Imamura et al. (18). The empiric formula below had a significant correlation
(r = 0.795) and good agreement with the measured central venous
pressure (mean difference -0.14 ± 1.77 mm Hg). Applying the above
equation to the validation cohort showed a strong association with
measured central venous pressure (r = 0.705).
Central venous pressure = 47.90-(0.086 × right atrial lead impedance) +
(0.013 × RV lead impedance)-(0.020 × LV lead impedance) (18).

2) Medical management
There is a growing recognition of the need to continue guidelinerecommended HF medications after LVAD implantation. Last year, we
referenced the lower mortality found when patients maintained HF
medications (19). In 2019, Mccolough et al. (20) showed similar results
from a new analysis of the INTERMACS database. The overall utilization of
this therapy was low. At the 6-months post-LVAD implantation, only 16.2%
of patients were receiving triple therapy, and only 22.6% were receiving an
angiotensin converting enzyme inhibitor or angiotensin receptor blocker
(ACEI/ARBs) and a beta-blocker. The unadjusted 4-year survival estimate
for patients receiving neurohormonal blockers was 56.0% (95% CI, 54.5%57.5%), compared with 43.9% (95% CI, 40.5%-47.7%) for patients not
receiving them (p < 0.001). Also, patients receiving triple therapy with an
ACEI/ARB, a beta-blocker, and an aldosterone antagonist at 6-months
The VAD Journal: Review of 2019
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post-LVAD had the longest survival estimate at four years (66.4%; 95% CI,
63.1%-70.0%). In an adjusted model, however, survival benefit became
insignificant. The six-minute walk results were also better in the patient
cohort on HF medications (20). Another study summarized experiences
from two centers, and their data showed treatment with ACEI/ARBs was an
independent factor associated with decreased post-LVAD mortality (21).
2019 also yielded the first report on the tolerability of sacibutril/valsartan in
patients with LVADs (22). Out of five patients who started taking this
medication, three had to discontinue this drug due to hypotension-related
symptoms (22).
The favorable effect of LVAD on diabetes has been previously reported
(23-26); however, for the first time last year, we demonstrated a significant
reduction in fasting blood glucose after LVAD implantation in both diabetic
and non-diabetic patients (27). In diabetic patients, there was an overall
reduction in insulin requirements from an average of 29.2 units per day
before the LVAD to 16.2 units per day before discharge (p= 0.038) (27). In
addition, the beneficial effect of an LVAD on other metabolic and hormonal
variables, such as free and total testosterone, thyroid-stimulating hormone,
and free T4, was shown by Nguen et al. (28). Before implantation, 75% of
patients had insulin resistance, 86% of men and 39% of women had low
free testosterone, and 44% of patients had abnormal thyroid function.
There was a significant improvement in all of the measures following
implantation (p < 0.001 for all). Patients with a normal hemoglobin A1C (<
5.7%) following implantation also had a higher 1-year survival free of HF
readmissions (78% versus 23%; P < 0.001). Patients with metabolic
parameters within normal range following LVAD implantation also had
higher 1-year survival free of HF readmissions (92% versus 54%; p= 0.04).

Radiation Therapy in LVAD
A case of radiation therapy for lung cancer in a patient with a HM3 device was
reported in 2019, and radiotherapy appeared to be safe in terms of continued
LVAD function (29). In the past, there were eight case reports on radiation therapy
with LVADs (HMII and Heartware) in the radiation field (29). The maximal reported
doses received directly to a VAD was 4900 cGy with a mean of 1922 cGy for a
gastroesophageal junction tumor. None of the patients experienced LVAD-related
complications or pump malfunction (29).

Recovery Evaluation
Last year, we published the flow chart for recovery evaluation (30), based on the
work of the Berlin group (31). This year, Nir Uriel’s group at the University of
Chicago shared their reverse ramp test protocols (Table 1), which assess
myocardial recovery (32). The group routinely performs such tests at the 6–12
months post-LVAD implantation timepoints in patients <50 years of age with a
short duration of HF (<2–5 years). In the reverse ramp test, device speed is
reduced to minimal settings, which requires anticoagulation with an international
normalized ratio (INR) of 2–3.5 to limit the risk of device thrombosis.
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Interestingly, with progressive decreases in LVAD speed, and hence reloading of
the LV, the left ventricular ejection fraction improved from baseline post-VAD
(30.67% ±10.15%) to the last step (46.05% ±14.19%). The pulmonary capillary
wedge pressure also increased from 8.86 ±3.08 mm Hg to 12.50 ±2.04 mm Hg;
the mean pulmonary artery pressure remained stable; and the central venous
pressure increased minimally from 7.14 ±2.91 mm Hg to 8.17 ±3.34 mm Hg.
Cardiac output decreased slightly during the test from 5.92 ±0.55 L/min to 5.44
±0.51 L/min. As a result, three out of seven patients were suitable for pump
decommissioning (32).

Table 1. Reverse ramp protocol for different pumps
Initial
speed,
rpms

Rpm
decrease
per step

Time between
steps, minutes

Final
speed,
rpms

HeartWare

2,400

199

3

1,800

HMII

8,000

400

3

6,000

HM3

5,000

100

3

4,000

Echo parameters
recorded for each step

left ventricular end-diastolic diameter, left ventricular
end-systolic diameter, aortic valve opening, degree
of aortic insufficiency, and mitral regurgitation

Hemodynamic
parameters recorded for
each step

central venous pressure; systolic, diastolic and
mean pulmonary artery pressure; pulmonary
capillary wedge pressure; pulmonary artery
saturation; cardiac output; cardiac index

Pump parameters
recorded for each step

HM II and HM3: speed, pulsatility index, flow, power
Heartware: speed, upper flow, lower flow, average
flow, power

Rpms – revolutions per minute; HMII – HeartMate II; HM3- HeartMate 3

LVAD and Valves
Mitral Valve
MitraClip (Abbott) is becoming an established procedure in many programs. So
far, LVADs have been implanted in patients with MitraClips, and reports indicate
the procedure is safe. Current data indicates that there is no need for additional
procedures on the mitral valve (33).

Aortic Valve
New data were published about the importance of aortic regurgitation in LVADs. If
the regurgitant fraction exceeds 30%, one-year survival free of major adverse
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events (bleeding, stroke, pump thrombosis) was 44% compared to 67% in patients
without significant aortic insufficiency (P = 0.018) (34).
Transcatheter aortic valve replacement was again found to be a feasible and safe
procedure in LVAD patients, resulting in complete resolution of aortic regurgitation
(35).

Tricuspid valve
The topic of concomitant procedures on the tricuspid valve during LVAD
implantation remains controversial. By some data, such procedures did not
improve patient outcomes but reduced the incidence of 30-day readmission (36).
Other data indicates the concomitant procedure increased cardiac output with
unknown clinical consequences (37).

Arrhythmia
There was an important analysis of the site of origin of ventricular tachycardia in
LVADs (38). Scar-related re-entry was the predominant mechanism (90.3%), and
cannula-related ventricular tachycardia was found only in 19.3% cases. In cases of
electrical storm, ablation was successful in 90% of the cases (38).
Ventricular arrhythmia continues to be an indicator of increased mortality after
LVAD. When ventricular arrhythmia occurs in the first month after LVAD
implantation, especially if presenting as electrical storm, it was associated with a 7fold increase of 30-day mortality (39). Fortunately, after the patients are
discharged alive, early ventricular arrhythmias have no further bearing on the
prognosis (39). Congruently, in another study, 32.8% of patients presenting with
electrical storm died within the next two weeks (40). Electrical storm was defined
as at least three separate episodes of sustained ventricular tachycardia or
appropriate implantable cardioverter defibrillator (ICD) shocks within a 24-hour
period (40).
Two new observational studies from Cleveland Clinic analyzed the presence of
ICDs (41) and atrial fibrillation/flutter (42) in LVAD patients. Neither was associated
with different outcomes than in patients without ICDs or atrial tachyarrhythmia,
respectively. There do not seem to be strong data in favor of implanting ICDs in
patients who did not have them before the LVAD (41). Also, there is no evidence
that controlling the rate in atrial arrhythmias improves outcomes. Atrial fibrillation or
flutter was not associated with increased mortality, thromboembolism, or bleeding
(38, 42).
Also, this year, a scientific statement from the American Heart Association was
published. It provides detailed recommendations on the management of
arrhythmias in LVAD recipients (43).
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Complications of the VADs
LVAD Outflow graft obstruction
Last year, we dedicated a significant portion of the review to outflow graft
obstruction research. The following summarizes the findings:
•
•
•
•
•
•
•

Surgical Technique: Gore-tex around the outflow tract
Timing: Months to years after the implantation
Symptoms: HF, low flows, with or without low flow alarm, and decreased
pulsatility index
Hemolysis: No
Diagnosis: Computer tomography angiography (CTA)
Treatment: Stenting
Prevention: Discontinuation of wrapping the outflow tract with the Gore-tex
(30)

However, despite several published cases and case series, the incidence of this
complication remains unknown. In a 2019 retrospective study, all patients with
CTAs done for any reason were examined for the outflow graft narrowing, defined
as the internal luminal diameter of the outflow graft < 10 mm (44). 14% of patients
had evidence of outflow graft lumen narrowing, all in HeartMate® devices and all
within the portion covered by the bend relief, with biodebris between the bend
relief and the outflow graft. Time from implant to scan (p < 0.001), nonischemic
cardiomyopathy (p= 0.017), and patient age at the device implant (p= 0.003) were
significantly associated with LVAD outflow graft narrowing (44).
Because patients had a CTA for clinical reasons, one of which is suspected pump
thrombosis or low flow state, this incidence rate may be higher than in all LVAD
recipients. Curiously, in this series, there were no cases of outflow graft
obstruction in HeartWare® devices. Authors postulate that the HeartWare design
allows greater accumulation of debris without lumen narrowing (44). However, last
year, we summarized published case reports, which included four cases of outflow
graft obstruction in HeartWare pumps. This year, Nathan et al. published the
largest case series of 12 outflow graft obstruction cases (45). 25% (3/12) cases
occurred with the HeartWare device. Another series of note included five patients
(46); four of these cases had HeartWare devices.

Stroke
Since the Evaluate the HeartWare Ventricular Assist System for Destination
Therapy of Advanced Heart Failure (ENDURANCE) Trial was published in 2017
(47), the increased rate of strokes on HeartWare devices as compared to HMII
support (29.7% vs. 12.1%, P<0.001) has been heeded by many as a word of
caution when it comes to the choice of pump.
However, in 2019, Li et al. identified and analyzed neurologic events in key clinical
trials and registries (48). He compared the HMII, HM3, and HeartWare devices
and found the neurologic event rates were comparable when standardized as
events per patient-year (HM3 = 0.17-0.21; HMII = 0.19-0.26; HeartWare = 0.160.28) (48). It appears that patient selection was key to the earlier reported
discrepancies, and no pump outperforms others in terms of stroke rate.
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Gastrointestinal Bleeding
Gastrointestinal bleeding on LVAD support is a frustrating complication requiring
extensive work up in search of a bleeding cause and location. Axelrad et al.
proposed an algorithm for LVAD-associated GIB (49). Adherence to this algorithm
was associated with a 68% increase in the diagnostic yield and a 113% increase in
the therapeutic yield of endoscopy. Also, it decreased the length of stay by four
days and reduced the number of procedures per patient by 27% and cost by 18%
(Figure 4).

Figure 4. Algorithm for diagnostic workup for gastrointestinal bleeding.
Modified from Axelrod et al. (49)

In terms of treatment, there is growing evidence that the medical management of
patients on LVAD may produce benefits seemingly unrelated to HF, BP control, or
LV reverse remodeling. In the retrospective cohort from of the University of
Minnesota, ACEI/ARB use was associated with a reduction in the incidence rate of
GIB (unadjusted 78% reduction; 95% CI, 0.10-0.48; p < 0.00001; adjusted 67%
reduction; 95% CI, 0.15-0.71; p= 0.005) (50). This protective effect is similar to the
observations of Houston et al. (51).
Another new study also showed that patients who received an ACEI/ARBs within
30 days after LVAD implantation had a 57% reduction in the risk of major GIB,
defined as bleeding requiring ≥ 2 units of packed red blood cells or resulting in
death (HR, 0.43; 95% CI, 0.19-0.97; p= 0.042) and a 63% reduction in the risk of
The VAD Journal: Review of 2019
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arterio-venous malformations-related GIB. Moreover, when the mean daily
lisinopril-equivalent ACEI /ARB dose was >5 mg, the risk of major GIB decreased
in a dose-threshold manner (HR, 0.28; 95% CI, 0.09-0.85; p= 0.025). Prevention of
the development of arterio-venous malformations was proposed as a potential
mechanism (52).
Other medications may also play a role in GIB. A retrospective review found that
selective serotonin reuptake inhibitors, commonly prescribed for depression, are
associated with GIB post-LVAD (53). Patients receiving these medications
developed GIB due to arterio-venous malformations at the rate of 24.8% versus
14.7% in patients not receiving them (53).
Thalidomide therapy was again found to be effective for GIB in LVAD patients,
reducing the risk of rebleeding (HR, 0.23; p= 0.022). The median number of GI
bleeds per year was reduced from 4.6 to 0.4 (p= 0.0008), and the packed red
blood cell requirement was lower (36.1 vs. 0.9 units per year, p= 0.004) in those
on thalidomide therapy. The adverse event rate with thalidomide was high at 59%,
with symptoms resolution in most following dose reduction without increased
bleeding (54).

RV failure
An interesting case was reported from the University of Toronto, where a patient
with an LVAD and RV failure progressed to asystole with a complete cardiac
standstill (55). Her hemodynamics were maintained by LVAD with no contribution
from the RV until she received a heart transplant (55). In an equally interesting
commentary, Imamura (56) compared this case with the one a patient on LVAD
support and sustained ventricular fibrillation. He suggested that in such cases of
"Fontan-like circulation," with LVAD performing the function of the LV and RV
being completely passive, circulation can be maintained with the following
hemodynamic parameters: central venous pressure of 15–20 mm Hg, pulmonary
capillary wedge pressure of 10–15 mm Hg, and low PVR around 2.0 Wood units
(56). An elevated central venous pressure was needed because a relatively highvolume status is required to maintain the preload of LV without any help from the
RV.

What is new in VA ECMO World?
The 2019 American Heart Association Focused Update on Advanced
Cardiovascular Life Support confirmed that there is insufficient evidence to
recommend the routine use of extracorporeal cardiopulmonary resuscitation
(ECPR) for patients with cardiac arrest (57). ECPR may be considered for selected
patients as rescue therapy when conventional CPR efforts are failing in settings in
which it can be expeditiously implemented and supported by skilled providers
(Class 2b; Level of Evidence C-LD) (57).
Like in continuous-flow LVADs, blood management on VA ECMO remains a topic
of discussion. While lower pressure can lead to end-organ hypoperfusion, a higher
pressure may compete with ECMO flow and cardiac output. In a retrospective
study of 124 patients, the average MAP was significantly higher in patients who
survived to discharge (82 ± 5.6 vs. 78 ± 5.5 mm Hg, p= 0.0003) (58). Survival was
best with a MAP higher than 90 mm Hg (71%) and worst with a MAP less than
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70 mm Hg, where no patient survived. MAP was an independent predictor of
survival to discharge by multivariate analysis (odds ratio 1.17, p= 0.013). Also,
patients with a higher MAP had a lower incidence of kidney injury (p= 0.007) (58).
For the first time, the excessive fluid accumulation while on VA ECMO support was
directly linked to increased short-term mortality (59). The net fluid balance was
higher in non-survivors than in survivors on Day 1 ECMO support (47.3 [18.1-71.9]
vs 19.3 [1.5-36.2] mL/kg, p < 0.0001) and Day 2 (30.6 [14.8-71.0] vs 10.1 [-9.834.7] mL/kg, p = 0.025), as was the cumulative fluid-balance over the first 5 days
(107.3 [40.5-146.2] vs 53.0 [7.5-74.3] mL/kg, p = 0.04). Moreover, a threshold of
38.8 mL/kg predicted mortality with a sensitivity of 60% and specificity of 83%
(59).
Another topic of growing interest is LV venting. A systematic literature review
analyzed mortality on VA ECMO based on the timing of LV venting (60). Overall,
LV venting significantly improved weaning from VA ECMO (odds ratio, 0.62; 95%
CI, 0.47-0.83; p= 0.001) and reduced 30-day mortality (risk ratio 0.86; 95% CI,
0.77-0.96; p= 0.008) but not in-hospital or 6-month mortality. Importantly, early (<
12 hours) but not late (≥ 12 hours) LV venting reduced short-term mortality
signficantly. In terms of the method of venting, the majority of patients had an intraaortic balloon pump (43%) (60).
Another analysis of published literature found that the intra-aortic balloon pump
was chosen as a venting device in 91.7% of patients on VA ECMO who had LV
venting (61). Mortality was lower in patients with (54%) versus without (65%) LV
unloading while on VA-ECMO (risk ratio, 0.79; 95% CI, 0.72-0.87; p < 0.00001)
(61).
Along the same lines, Vallabhassula et al. (62) reviewed the literature to compare
early mortality in patients with cardiogenic shock treated with ECMO plus Impella
(Abiomed) (ECPELLA) to VA ECMO alone. They found that the use of ECPELLA
was associated with higher weaning from VA ECMO and bridging to permanent
LVAD or cardiac transplant. Also, the studies that accounted for differences in
baseline characteristics between treatment groups reported lower 30-day mortality
with ECPELLA versus VA ECMO (62).
LV venting with a transseptal 24-Fr multiple-side-hole cannula with a length of > 55
cm that could effectively decompress both the right and left heart was reported by
Na et al. (63). If the device was used prophylactically, before LV distension, the
30-day mortality rate was 5.6%, but if the cannula was inserted for treatment of LV
distension after it occurred, the mortality was 34.4% (P= 0.036). The rate of
successful weaning from ECMO and the duration of ECMO support were not
significantly different between the groups. However, the rate of bridging to cardiac
replacement therapy, such as heart transplantation or LVAD, was significantly
higher in the prophylactic group (66.7%) than in the therapeutic group (37.5%) (P=
0.048) (63).
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